Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib.
cardiovascular
model informed drug development
modeling and simulation
pharmacodynamics
pharmacometrics
population pharmacokinetics
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
22
02
2024
accepted:
03
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
Obicetrapib is a selective inhibitor of cholesteryl ester transfer protein that is currently in phase 3 of development for the treatment of dyslipidemia as adjunct therapy. The purpose of this study was to comprehensively characterize the pharmacokinetic (PK) and pharmacodynamic (PD) disposition of obicetrapib. Data from 7 clinical trials conducted in healthy adults and those with varying degrees of dyslipidemia were included for model development. The structural model that best described obicetrapib PK was a 3-compartment model with 4-compartment transit absorption and first-order elimination. Body weight was the only covariate found to significantly explain observed variability and was therefore included using allometric scaling on all disposition parameters. For a typical patient weighing 75 kg, the estimated apparent total body clearance and apparent volume of distribution of the central compartment was 0.81 L/h and 36.1 L, respectively. The final PK model parameters were estimated with good precision and were ultimately leveraged to sequentially inform 2 turnover models that describe obicetrapib's effect on low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) concentrations. The maximum stimulatory effect of obicetrapib on LDL-C loss was estimated to be 1.046, while the maximum inhibitory effect of obicetrapib on HDL-C loss was 0.691. This corresponds to a predicted typical maximum percent change from baseline LDL-C and HDL-C of 51.1% and 224%, respectively. The final sequential model described obicetrapib PKPD well and was ultimately able to both demonstrate evidence of internal consistency and support decision-making throughout the development lifecycle.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024, The American College of Clinical Pharmacology.
Références
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2019 Jun 25;73(24):3234‐3237]. J Am Coll Cardiol. 2019;73(24):3168‐3209. https://doi.org/10.1016/j.jacc.2018.11.002
Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350‐2473. https://doi.org/10.1016/j.jacc.2023.11.007
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689‐700. https://doi.org/10.1038/s41569‐021‐00541‐4
Balling M, Nordestgaard BG, Langsted A, Varbo A, Kamstrup PR, Afzal S. Small dense low‐density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen general population study. J Am Coll Cardiol. 2020;75(22):2873‐2875. https://doi.org/10.1016/j.jacc.2020.03.072
Noncommunicable diseases: risk factors. World Health Organization. Accessed February 13, 2024. https://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/
Raised cholesterol. World Health Organization. Accessed February 13, 2024. https://www.who.int/data/gho/indicator‐metadata‐registry/imr‐details/3236
Desai CS, Martin SS, Blumenthal RS. Non‐cardiovascular effects associated with statins. BMJ. 2014;349:g3743. https://doi.org/10.1136/bmj.g3743
Mahase E. Half of patients prescribed statins fail to hit target reduction in LDL cholesterol. BMJ. 2019;365:l1838. https://doi.org/10.1136/bmj.l1838
Krähenbühl S, Pavik‐Mezzour I, von Eckardstein A. Unmet needs in LDL‐C lowering: when statins won't do!. Drugs. 2016;76(12):1175‐1190. https://doi.org/10.1007/s40265‐016‐0613‐0
Hewing B, Moore KJ, Fisher EA. HDL and cardiovascular risk: time to call the plumber? Circ Res. 2012;111(9):1117‐1120. https://doi.org/10.1161/CIRCRESAHA.112.280958
Randomized study to evaluate the effect of obicetrapib on top of maximum tolerated lipid‐modifying therapies (BROADWAY). ClinicalTrials.gov identifier: NCT05142722. Updated September 18, 2023. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT05142722
Evaluate the effect of obicetrapib in patients with HeFH on top of maximum tolerated lipid‐modifying therapies (BROOKLYN). ClinicalTrials.gov identifier: NCT05425745. Updated January 23, 2024. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT05425745
Cardiovascular outcome study to evaluate the effect of obicetrapib in patients with cardiovascular disease (PREVAIL). ClinicalTrials.gov identifier: NCT05202509. Updated January 24, 2024. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT05202509
Study of obicetrapib & ezetimibe fixed dose combination on top of maximum tolerated lipid‐modifying therapies (TANDEM). ClinicalTrials.gov identifier: NCT06005597. Updated January 23, 2024. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT06005597
Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high‐intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672‐1678. https://doi.org/10.1038/s41591‐022‐01936‐7
Evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of TA‐8995 with single, escalating doses in healthy subjects. ClinicalTrials.gov identifier: NCT01878474. Updated June 17, 2013. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT01878474
Evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of TA‐8995 after multiple doses in healthy subjects. ClinicalTrials.gov identifier: NCT01879020. Updated June 17, 2013. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT01879020
TA‐8995: its use in patients with mild dyslipidaemia (TULIP). ClinicalTrials.gov identifier: NCT01970215. Updated August 21, 2014. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT01970215
Randomized study of obicetrapib as an adjunct to statin therapy (ROSE). ClinicalTrials.gov identifier: NCT04753606. Updated September 5, 2021. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT04753606
Study to evaluate the effect of obicetrapib in combination with ezetimibe as an adjunct to HIS therapy (ROSE2). ClinicalTrials.gov identifier: NCT05266586. Updated October 12, 2022. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT05266586
A dose‐finding study in Japanese patients to evaluate the effect of obicetrapib as an adjunct to stable statin therapy. ClinicalTrials.gov identifier: NCT05421078. Updated September 7, 2023. Accessed February 13, 2024. https://clinicaltrials.gov/study/NCT05421078
Ford J, Lawson M, Fowler D, et al. Tolerability, pharmacokinetics and pharmacodynamics of TA‐8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2014;78(3):498‐508. https://doi.org/10.1111/bcp.12380